Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.47 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.47 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.47 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.47 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.47 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.47 |
| ▸ | ACE | P12821 | 1/20 | 0.47 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | PREP | P48147 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7489292 | 1.00 | POLB (0.62) | POLBSMN1; SMN2NPC1RAB9APSEN1 | |
| SCHEMBL31037789 | 1.00 | POLB (0.62) | POLBSMN1; SMN2NPC1RAB9APSEN1 | |
| SCHEMBL115923 | 1.00 | POLB (0.62) | POLBSMN1; SMN2NPC1RAB9APSEN1 | |
| SCHEMBL464289 | 1.00 | POLB (0.62) | POLBSMN1; SMN2NPC1RAB9APSEN1 | |
| SCHEMBL7016734 | 1.00 | POLB (0.62) | POLBSMN1; SMN2NPC1RAB9APSEN1 | |
| SCHEMBL71529 | 1.00 | POLB (0.62) | POLBSMN1; SMN2NPC1RAB9APSEN1 | |
| SCHEMBL71528 | 1.00 | POLB (0.62) | POLBSMN1; SMN2NPC1RAB9APSEN1 | |
| SCHEMBL28269 | 1.00 | POLB (0.62) | POLBSMN1; SMN2NPC1RAB9APSEN1 | |
| SCHEMBL23485199 | 0.90 | POLB (0.61) | POLBSMN1; SMN2NPC1RAB9APSEN1 | |
| SCHEMBL30564487 | 0.90 | POLB (0.61) | POLBSMN1; SMN2NPC1RAB9APSEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240287138-A1 | CYCLIC PEPTIDES FOR INHIBITING TNF RECEPTOR 1 ACTIVITY | MERCK SHARP & DOHME LLC | 2024-08-29 | — | — | US | disclosed |
| US-11780826-B2 | Bisamide sarcomere activating compounds and uses thereof | AMGEN INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-11274100-B2 | EP300/CREBBP inhibitor | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-03-15 | — | — | US | disclosed |
| US-20210171520-A1 | EP300/CREBBP INHIBITOR | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2021-06-10 | — | — | US | disclosed |
| US-20210171520-A1 | EP300/CREBBP INHIBITOR | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2021-06-10 | — | — | US | disclosed |
| EP-3643703-A1 | EP300/CREBBP INHIBITOR | Daiichi Sankyo Co., Ltd. (JP) | 2020-04-29 | — | — | EP | disclosed |
| US-20130231373-A1 | HYDROXAMATE-BASED INHIBITORS OF DEACETYLASES | NOVARTIS AG (CH) | 2013-09-05 | — | — | US | disclosed |
| US-20130231373-A1 | HYDROXAMATE-BASED INHIBITORS OF DEACETYLASES | NOVARTIS AG (CH) | 2013-09-05 | — | — | US | disclosed |
| EP-2609078-A1 | HYDROXAMATE-BASED INHIBITORS OF DEACETYLASES | Novartis AG (CH) | 2013-07-03 | — | — | EP | disclosed |
| US-8203003-B2 | 4-fluoropyrrolidine-2-carbonyl fluoride compounds and their preparative methods | UBE INDUSTRIES, LTD. (JP) | 2012-06-19 | — | — | US | disclosed |
| WO-2012025164-A1 | HYDROXAMATE-BASED INHIBITORS OF DEACETYLASES | NOVARTIS AG (CH) | 2012-03-01 | — | — | WO | disclosed |
| WO-2012025164-A1 | HYDROXAMATE-BASED INHIBITORS OF DEACETYLASES | NOVARTIS AG (CH) | 2012-03-01 | — | — | WO | disclosed |
| US-20110275833-A1 | Novel 4-Fluoropyrrolidine-2-Carbonyl Fluoride Compounds and Their Preparative Methods | UBE INDUSTRIES, LTD. (JP) | 2011-11-10 | — | — | US | disclosed |
| US-20110060009-A1 | Hydroxamate-Based Inhibitors of Deacetylases | NOVARTIS AG | 2011-03-10 | — | — | US | disclosed |
| US-20110060009-A1 | Hydroxamate-Based Inhibitors of Deacetylases | NOVARTIS AG | 2011-03-10 | — | — | US | disclosed |
| US-20100190688-A1 | Tetrapeptide analogs | IDUN PHARMACEUTICALS, INC. | 2010-07-29 | — | — | US | disclosed |
| WO-2010081014-A1 | NOVEL 4-FLUOROPYRROLIDINE-2-CARBONYL FLUORIDE COMPOUNDS AND THEIR PREPARATIVE METHODS | IM&T RESEARCH, INC. (US) | 2010-07-15 | — | — | WO | disclosed |
| US-20100174096-A1 | Methods for Production of Optically Active Fluoropyrrolidine Derivatives | IM&T RESEARCH, INC. (US) | 2010-07-08 | — | — | US | disclosed |
| CN-1101908-A | Angiotensin II antagonists | LILLY CO ELI (US) | 1995-04-26 | — | — | CN | disclosed |
| EP-0324543-A2 | Antiarrhythmic agents | Pfizer Limited (GB) | 1989-07-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11274100-B2 | EP300/CREBBP inhibitor | EP300, CREBBP, CREB1 | POLB 1653/4885SMN1; SMN2 4058/4885NPC1 2688/4885 |
| US-20130231373-A1 | HYDROXAMATE-BASED INHIBITORS OF DEACETYLASES | HDAC1, HDAC11, HDAC3 | POLB 2195/4885SMN1; SMN2 2867/4885NPC1 684/4885 |
| US-11780826-B2 | Bisamide sarcomere activating compounds and uses thereof | TNNI3, TNNT2, TNNC1 | POLB 2801/4885SMN1; SMN2 126/4885NPC1 4666/4885 |
| US-20110275833-A1 | Novel 4-Fluoropyrrolidine-2-Carbonyl Fluoride Compounds and Their Preparative Methods | PFAS, AFF4, PAICS | POLB 1820/4885SMN1; SMN2 1423/4885NPC1 1388/4885 |
| US-20100174096-A1 | Methods for Production of Optically Active Fluoropyrrolidine Derivatives | QDPR, FDPS, DPYD | POLB 1745/4885SMN1; SMN2 3187/4885NPC1 3347/4885 |
| US-20240287138-A1 | CYCLIC PEPTIDES FOR INHIBITING TNF RECEPTOR 1 ACTIVITY | TNF, TNFRSF1A, CD40 | POLB 3557/4885SMN1; SMN2 2974/4885NPC1 2791/4885 |
| US-20210171520-A1 | EP300/CREBBP INHIBITOR | EP300, CREBBP, CREB1 | POLB 1653/4885SMN1; SMN2 4058/4885NPC1 2688/4885 |
| US-20100190688-A1 | Tetrapeptide analogs | TP53, PCNA, HRAS | POLB 97/4885SMN1; SMN2 1678/4885NPC1 2779/4885 |
| US-20110060009-A1 | Hydroxamate-Based Inhibitors of Deacetylases | HDAC1, HDAC11, HDAC3 | POLB 2226/4885SMN1; SMN2 2787/4885NPC1 650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.